[go: up one dir, main page]

ATE417605T1 - Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität - Google Patents

Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität

Info

Publication number
ATE417605T1
ATE417605T1 AT03762927T AT03762927T ATE417605T1 AT E417605 T1 ATE417605 T1 AT E417605T1 AT 03762927 T AT03762927 T AT 03762927T AT 03762927 T AT03762927 T AT 03762927T AT E417605 T1 ATE417605 T1 AT E417605T1
Authority
AT
Austria
Prior art keywords
cross
beta structure
modulating
formation
methods
Prior art date
Application number
AT03762927T
Other languages
English (en)
Inventor
Martijn Gebbink
Barend Bouma
Onno Kranenburg
Louise Kroon
Original Assignee
Crossbeta Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossbeta Biosciences Bv filed Critical Crossbeta Biosciences Bv
Application granted granted Critical
Publication of ATE417605T1 publication Critical patent/ATE417605T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9726—Tissue plasminogen activator
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
AT03762927T 2002-07-09 2003-07-08 Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität ATE417605T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077797A EP1380290A1 (de) 2002-07-09 2002-07-09 Cross-Beta-Strukturweg und seine therapeutische Relevanz

Publications (1)

Publication Number Publication Date
ATE417605T1 true ATE417605T1 (de) 2009-01-15

Family

ID=29724525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03762927T ATE417605T1 (de) 2002-07-09 2003-07-08 Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität

Country Status (13)

Country Link
US (3) US20060045853A1 (de)
EP (5) EP1380290A1 (de)
JP (1) JP2005537254A (de)
AT (1) ATE417605T1 (de)
AU (2) AU2003251233B2 (de)
CA (1) CA2492010A1 (de)
DE (1) DE60325381D1 (de)
DK (1) DK1536778T3 (de)
ES (1) ES2319982T3 (de)
NZ (2) NZ537495A (de)
PT (1) PT1536778E (de)
WO (1) WO2004004698A2 (de)
ZA (1) ZA200500062B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1704867A1 (de) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-Beta Strukturen auf Mikrobenorganismen
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
CA2615078A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Methods for determining the effect of a treatment on the cross-.beta. structure content of a protein; selection of treatments and uses thereof
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
EP2386861A3 (de) * 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-Beta-Struktur-bindende Verbindungen
CA2645930A1 (en) * 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
GB0710976D0 (en) 2007-06-07 2007-07-18 Bioalvo Am Screening method
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
CN107677829A (zh) * 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
JP5432923B2 (ja) 2008-12-22 2014-03-05 学校法人藤田学園 Ａβ除去材、Ａβ除去器及びＡβ除去システム
EP2322163A1 (de) * 2009-11-03 2011-05-18 Pharnext Neue therapeutische Ansätze zur Behandlung von Alzheimer-Krankheit
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
US20130122076A1 (en) * 2011-11-11 2013-05-16 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
TWI859887B (zh) * 2023-05-26 2024-10-21 國立臺北科技大學 應用顯微鏡式圓二色光譜檢測系統的檢測方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60103964A (ja) * 1983-11-10 1985-06-08 ユニチカ株式会社 抗血栓性材料
US5700447A (en) 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733524A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
ATE70301T1 (de) * 1986-02-17 1991-12-15 Stichting Centraal Lab Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
EP0319144A1 (de) 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Sorbentmittel für beta-2-Mikroglobulin
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US5216127A (en) 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
US5151082A (en) * 1988-08-05 1992-09-29 Heathdyne, Inc. Apparatus and method for kidney dialysis using plasma in lieu of blood
US5679320A (en) * 1988-12-29 1997-10-21 Bio-Technology General Corp. Fibrin binding domain polypeptides and uses and methods of producing same
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5180615A (en) * 1989-12-13 1993-01-19 W.R. Grace & Co.-Conn. Metallized bag for static protection of electronic components
US5591431A (en) * 1990-03-09 1997-01-07 G.D. Searle & Co. Enhancement of clot lysis
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
SE502414C2 (sv) * 1990-05-28 1995-10-16 Ljungqvist Olle Medical Ab Användning av glukos för framställning av lösning för preoperativ administrering samt infusionslösning därför
WO1991019488A1 (en) * 1990-06-04 1991-12-26 Therapy 2000 REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5650418A (en) 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
SE468881B (sv) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
US5221628A (en) * 1991-03-19 1993-06-22 Northwestern University Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
HUT64977A (en) 1992-07-30 1994-03-28 Yeda Res & Dev Synthetical peptone derivatives of vitronectine and pharmaceutical preparaties containing them
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5449663A (en) * 1993-06-11 1995-09-12 Bicher; Haim I. Antineoplastic compositions
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
ATE249234T1 (de) * 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
AU692237B2 (en) 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6410598B1 (en) * 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
KR0163563B1 (ko) * 1994-03-23 1998-12-01 김종인 피부질환 치료용 의약조성물
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6136548A (en) 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
JPH11514333A (ja) * 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
JPH11513490A (ja) * 1995-10-02 1999-11-16 カトット，モハメド，ダブリュ． 生物学的活性ポリマー
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6310046B1 (en) * 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
AU1529297A (en) * 1996-01-24 1997-08-20 Warner-Lambert Company Method of imaging amyloid deposits
US5785187A (en) * 1996-04-29 1998-07-28 Lipman; Daniel Mechandising display assembly
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
US6929807B1 (en) * 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
WO1998006418A1 (en) * 1996-08-09 1998-02-19 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6689275B1 (en) * 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US20020122807A1 (en) 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
CA2295375A1 (en) * 1997-07-08 1999-01-21 Novopharm Biotech Inc. Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
DE19735902A1 (de) * 1997-08-19 1999-02-25 Imtec Immundiagnostika Gmbh Selektives Adsorbens für biologische Materialien
AU9125798A (en) 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
AU760140B2 (en) * 1997-10-24 2003-05-08 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
AU2905699A (en) * 1998-03-18 1999-10-11 Tyndale Plains-Hunter Ltd. Hydrophilic polyether polyurethanes containing carboxylic acid
JP4037525B2 (ja) 1998-03-25 2008-01-23 生化学工業株式会社 新規抗菌性ペプチド
US7041287B2 (en) * 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots
US6416963B1 (en) 1998-08-12 2002-07-09 New York Blood Center Cleaved fragments of fibrinogen
EP1115396A4 (de) * 1998-09-25 2002-05-22 Sunol Molecular Corp Pharmazeutisch aktive verbindungen und deren verwendungsmethoden
IN190822B (de) * 1998-12-24 2003-08-23 Council Scient Ind Res
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6161547A (en) * 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
EP1165079A2 (de) * 1999-04-06 2002-01-02 Kansas University Medical Center Verbesserte dialyse lösungen und verfahren
WO2000066717A1 (fr) * 1999-04-30 2000-11-09 Akira Matsumoto Carboxypeptidase b du cerveau humain
ATE384077T1 (de) * 1999-05-05 2008-02-15 Neurochem Int Ltd Stereoselektive antifibrillogene peptide
AT500670A1 (de) * 1999-05-19 2006-02-15 Bio & Bio Licensing Sa Arzneimittel zur lokalen anwendung
US6582945B1 (en) * 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
GB9917725D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
CA2382095A1 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
EP1174434A1 (de) * 1999-09-14 2002-01-23 Meiji Seika Kaisha Ltd. Phosphonsäurederivat mit hemmender Wirkung gegen Carboxypeptidase B
US6399314B1 (en) * 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
EP1252181B1 (de) 2000-01-20 2006-01-18 Regents Of The University Of Minnesota Peptide mit antibakterieller wirkung
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
EE200200444A (et) 2000-02-21 2003-12-15 Pharmexa A/S Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
EP1130031A1 (de) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Verfahren zur Hemmung der Angiogenese unter Verwendung von Molekülen die die Plasminbildung steigern oder die Plasminaktivität verlängern
AU2001247667A1 (en) * 2000-03-21 2001-10-03 Research Foundation Of State University Of New York Adsorption of polyampholytes to charged surfaces and assays incorporating same
DE10017690A1 (de) * 2000-04-08 2001-10-25 Simmoteit Robert Vorrichtung zum Stoffaustausch und Kultivierung von Zellen
HU230375B1 (hu) 2000-08-24 2016-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
US7029655B2 (en) * 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
DE60032250T2 (de) * 2000-12-28 2007-03-15 Biomay Produktions- Und Handels-Aktiengesellschaft Behandlung von Allergien
EP1383885A4 (de) * 2001-04-04 2005-11-30 American Diagnostica Inc Verfahren zur herstellung eines stabilisierten, mit thrombin aktivierbaren fibrinolyseinhibitors (tafi) sowie verfahren zu dessen verwendung
EP1395833B1 (de) 2001-05-31 2013-02-27 Adlyfe, Inc. Verfahren zum erkennen von inkorrekt gefalteten proteinen
US6960465B1 (en) * 2001-06-27 2005-11-01 Northwestern University Increased cell resistance to toxic organic substances
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CA2453403C (en) * 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
JP2003024080A (ja) * 2001-07-19 2003-01-28 Univ Tokyo ｐ５３依存性アポトーシス誘導タンパク質、およびアポトーシス調節剤のスクリーニング方法
GB0202275D0 (en) 2002-01-31 2002-03-20 Hansa Medica Ab Peptide
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
NZ535276A (en) 2002-02-28 2008-04-30 Microsens Biophage Ltd Binding of pathological forms of prion proteins
US20050142208A1 (en) * 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (de) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US20050142611A1 (en) * 2002-09-30 2005-06-30 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
EP1449536A1 (de) 2003-02-14 2004-08-25 Prionics AG Prioproteine als therapeutische mittel zur behandlung von AP-1 assoziierten krankheiten
US7172875B2 (en) * 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
US20080299212A1 (en) * 2005-02-25 2008-12-04 Medigenes Co., Ltd Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum
EP1704867A1 (de) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-Beta Strukturen auf Mikrobenorganismen
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP2386861A3 (de) * 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-Beta-Struktur-bindende Verbindungen
CA2615078A1 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Methods for determining the effect of a treatment on the cross-.beta. structure content of a protein; selection of treatments and uses thereof
BRPI0613525A2 (pt) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv métodos para produzir uma composição imunogênica, para melhorar a imunogenicidade de uma composição, para intensificar a imunogenicidade de uma composição de vacina, e para determinar a quantidade de estruturas beta-cruzadas em uma composição de vacina, usos de estruturas beta-cruzadas, e de uma composição imunogênica, vacina de subunidade, e, composição imunogênica
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US20070015133A1 (en) 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
WO2007018400A1 (en) 2005-08-11 2007-02-15 Medigenes Co., Ltd Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum
US8543424B2 (en) * 2005-12-30 2013-09-24 Darryl Mark Hunsaker Vehicle insurance status display system
CA2645930A1 (en) 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen

Also Published As

Publication number Publication date
EP2341348A1 (de) 2011-07-06
ES2319982T3 (es) 2009-05-18
AU2010200343A1 (en) 2010-02-18
DE60325381D1 (de) 2009-01-29
EP1380290A1 (de) 2004-01-14
EP2322154A2 (de) 2011-05-18
NZ561168A (en) 2009-06-26
EP1978362A3 (de) 2009-02-11
PT1536778E (pt) 2009-03-24
AU2003251233A1 (en) 2004-01-23
CA2492010A1 (en) 2004-01-15
JP2005537254A (ja) 2005-12-08
US8158585B2 (en) 2012-04-17
EP1536778B1 (de) 2008-12-17
US20060045853A1 (en) 2006-03-02
US20080241165A1 (en) 2008-10-02
EP2322154A3 (de) 2011-10-05
AU2003251233B2 (en) 2009-10-29
EP1978362A2 (de) 2008-10-08
NZ537495A (en) 2009-04-30
WO2004004698A3 (en) 2004-06-10
WO2004004698A2 (en) 2004-01-15
DK1536778T3 (da) 2009-04-14
US20120189615A1 (en) 2012-07-26
EP1536778A2 (de) 2005-06-08
ZA200500062B (en) 2005-11-01

Similar Documents

Publication Publication Date Title
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
DE60143192D1 (de) Zellen zur entdeckung von medikamenten
ATE535529T1 (de) Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
EP1629084A4 (de) Modulation der expression von c-reaktivem protein
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
DE69839444D1 (de) Smad 6 und dessen anwendungen
ATE463294T1 (de) Verfahren zur konzentration und reinigung von biologischen verbindungen
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
ATE439441T1 (de) Veränderte, fluoreszierende proteine
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
ATE405834T1 (de) Bindungsoberfläche
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
DK1622929T3 (da) Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
WO2001064837A8 (en) β NETRIN AND USES THEREOF
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE69924120D1 (de) Für ataxin-2-bindende proteine kodierende nukleinsäure, damit verwandten produkten und verfahren zur deren anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1536778

Country of ref document: EP